What does this research mean for the field?

Question

Accepted Answer

Pathogenic germline CHEK2 variants occur in approximately 2.2% of patients with early-onset or familial myeloproliferative neoplasms and are associated with a family history of malignancies and a higher risk of leukemic evolution. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

CHEK2 Germline Variants in Early‐Onset and Familial Myeloproliferative Neoplasms

Discussion

Member takes

Overview

Key Points

Cite This Study